Recently, the U.S. Food and Drug Administration (FDA)
approved
combined dosage forms of lesinurad (LND) and allopurinol (ALU) in
fixed-dose combinations to treat hyperuricemia associated with gout.
For the simultaneous estimation (SME) of LND and ALU, neither conventional
“high-performance thin-layer chromatography (HPTLC)”
nor a greener HPTLC approach has been published to date. This study
was carried out to design and validate a rapid, sensitive, and greener
normal-phase HPTLC technique for the SME of LND and ALU in FDA-approved
fixed-dose combination tablets. Ethyl acetate, ethanol, and water
in a ternary ratio of 70:20:10 (v/v/v) were employed as a greener
eluent system for the SME of LND and ALU. Normal-phase silica gel
60F254S plates were employed as the stationary phase. At a wavelength
of 240 nm, LND and ALU were simultaneously estimated. The current
method’s greenness was assessed using the National Environmental
Method Index (NEMI), Analytical Eco-Scale (AES), ChlorTox, and Analytical
GREENness (AGREE) methodologies. The current method was linear in
the 30–1200 ng/band range for LND and ALU. The current approach
was extensively validated and demonstrated to be accurate, precise,
robust, sensitive, and greener for the SME of LND and ALU. The results
of all greenness tools, including NEMI, AES (89), ChlorTox (0.96 g),
and AGREE (0.81) showed that the current approach had an exceptional
greener profile. Using the present methodology, the amounts of LND
in FDA-approved fixed-dose combinations A and B were measured to be
98.73 and 99.17%, respectively. Using the present methodology, the
amounts of ALU in FDA-approved fixed-dose combinations A and B were
determined to be 99.27 and 100.58%, respectively. These data support
the applicability of the current methodology for SME of LND and ALU
in FDA-approved products. The findings of this study suggested that
the current approach may be consistently applied to measure the LND
and ALU in FDA-approved products.